Abstract: FR-PO426
Tenapanor, a Novel Phosphorus Absorption Inhibitor, Softens Stool Properties and Enables Good Phosphorus Management
Session Information
- Hemodialysis Epidemiology and Outcomes
October 25, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 801 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Morii, Kenichi, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Japan
- Doi, Toshiki, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Japan
- Okubo, Aiko, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Japan
- Nishizawa, Yoshiko, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Japan
- Yamashita, Kazuomi, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Japan
- Mizuiri, Sonoo, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Japan
- Masaki, Takao, Hiroshima Daigaku, Hiroshima, Japan
Background
Tenapanor is a novel drug that reduces phosphorus absorption from the intestinal tract by inhibiting Na+/H+ exchanger isoform 3 (NHE3) in intestinal epithelial cells, thereby decreasing phosphorus permeability in the intercellular space. It is also used as a treatment for constipation-type irritable bowel syndrome (IBS-C) in the United States and Canada. Recently, tenapanor has become available as a hyperphosphatemic treatment for chronic kidney disease patients on dialysis. In this study, we investigated the effects of tenapanor on defecation status and serum phosphorus levels.
Methods
An observational study was conducted on 14 dialysis patients (12 hemodialysis patients, 1 peritoneal dialysis patient, and 1 peritoneal dialysis + hemodialysis hybrid patient) who started tenapanor at our affiliated institutions. A questionnaire was administered to assess the Bristol Stool Form Scale (BSFS: O’Donnell LJ, et al., BMJ 1990) and the number of defecations per week to evaluate the defecation status. Changes in defecation status and serum phosphorus levels after 8 weeks of tenapanor administration were examined.
Results
Four of the 14 patients discontinued medication due to diarrhea, one patient died due to cardiovascular events, and one patient was excluded due to withdrawal of consent. Data from eight individuals were analyzed. A significant difference was found in BSFS between 0 weeks and 8 weeks after starting tenapanor, 3.1 at 0 weeks, and 4.8 at 8 weeks (P<0.01). There was no significant difference in the number of defecations per week. Serum phosphorus levels were generally controlled within management goals.
Conclusion
Tenapanor can soften stool properties and control serum phosphorus levels well, although diarrhea has been observed as a side effect.